Category: Pharmaceuticals
-
Immunoprecise Antibodies (IPA.V), or should I say (NASDAQ: IPA)
Before we start, let’s give a big round of applause to Immunoprecise Antibodies Ltd and all its staff and its management. They are headed to the big leagues, ladies and gentlemen – a straight path towards listing on the Nasdaq (begin trading on Nasdaq on December 30th, 2020). I’m not a parent myself (unless you…
-
Revive Therapeutics (RVV.C) shareholders experience intense vertigo
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
-
Can scrappy Valeo Pharma (VPH.C) win a Stanley Cup?
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
-
Core One Labs (COOL.C): Out of the ashes, a new business model and supportive shareholder base
In my experience with the North American public markets, few companies and executive teams got more lucky with their shareholder base than Lifestyle Delivery Systems. Their initial pitch was simple – they’d put extracted cannabis on thin film strips for easy and precise ingestion – and I, along with a ton of others, shoveled money…
-
Numinus Wellness (NUMI.V) to partner on MDMA psychotherapy trial for PTSD patients
If this was a 1990’s news website we’d be putting all sorts of animated siren gifs all over the top of this piece because, I ain’t gonna lie: It’s a big one. Numinus Wellness (NUMI.V), who we’ve been eyeing at a distance for some time because we love shrooms as an industry but don’t trust…
-
Canntab Therapeutics’ (PILL.C) bursts out of the starting blocks with $1.3 million sale
PILL is developing solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in multiple doses and timed-release combinations
-
![Revive (RVV.C) stock ramps hard on news from a collaborator]()
Revive (RVV.C) stock ramps hard on news from a collaborator
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
-
![(ATHA.Q), (BIIB.Q), (SAVA.Q), (DRAD.Q), (SUPN.Q), (XLV.NYSE): Trump or Biden? Canadians freak out, healthcare stocks go ballistic]()
(ATHA.Q), (BIIB.Q), (SAVA.Q), (DRAD.Q), (SUPN.Q), (XLV.NYSE): Trump or Biden? Canadians freak out, healthcare stocks go ballistic
Sick democracy – sick people – big profits. That was a cogitative jump that most investors seemed to make.
-
![Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms]()
Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.
-
![Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market]()
Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market
Currently in Canada, the dry eye market is estimated at over $9O million, which includes both prescription and over-the-counter products.
